Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cy7.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  2. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  3. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  4. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  5. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  6. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  7. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  8. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  9. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  10. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  11. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  12. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  13. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  14. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  15. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  16. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  17. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  18. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  19. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  20. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  21. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  22. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  23. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  24. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  25. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  26. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  27. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  28. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  29. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  30. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  31. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  32. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  33. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  34. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  35. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  36. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  37. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  38. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  39. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  40. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  41. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  42. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  43. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  44. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  45. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  46. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  47. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  48. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  49. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  50. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  51. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  52. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  53. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  54. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  55. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  56. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  57. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  58. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  59. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  60. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  61. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  62. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  63. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  64. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  65. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  66. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  67. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  68. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  69. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  70. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  71. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  72. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  73. Woodruff MC, et al. 2022. Nature. :. PubMed
  74. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  75. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  76. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  77. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  78. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  79. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  80. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  81. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  82. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  83. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  84. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  85. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  86. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  87. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  88. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  89. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  90. Akiyama H, et al. 2020. J Virol. . PubMed
  91. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  92. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  93. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  94. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  95. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  96. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  97. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  98. Mills C, et al. 2022. Cells. 11:. PubMed
  99. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  100. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  101. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  102. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  103. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  104. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  105. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  106. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  107. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  108. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  109. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  110. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  111. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  112. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  113. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  114. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  115. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  116. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  117. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  118. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  119. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  120. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  121. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  122. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  123. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  124. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  125. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  126. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  127. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  128. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  129. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  130. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  131. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  132. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  133. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  134. Wang Z, et al. 2021. bioRxiv. . PubMed
  135. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  136. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  137. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  138. English KG, et al. 2022. Biomedicines. 10:. PubMed
  139. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  140. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  141. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  142. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  143. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  144. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  145. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  146. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  147. Woodruff M, et al. 2020. medRxiv. . PubMed
  148. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  149. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  150. Popay TM, et al. 2021. Elife. 10: . PubMed
  151. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  152. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  153. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  154. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  155. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  156. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  157. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  158. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  159. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  160. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  161. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  162. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  163. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  164. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  165. Elias G, et al. 2022. Elife. 11:. PubMed
  166. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  167. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  168. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  169. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  170. Ito Y, et al. 2018. Cell. 174:636. PubMed
  171. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  172. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  173. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  174. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  175. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  176. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  177. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  178. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  179. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  180. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  181. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  182. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  183. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  184. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  185. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  186. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  187. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  188. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  189. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  190. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  191. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  192. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  193. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  194. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  195. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  196. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  197. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  198. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  199. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  200. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  201. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  202. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  203. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  204. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  205. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  206. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  207. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  208. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  209. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  210. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  211. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  212. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  213. Wang Z, et al. 2021. Nature. 592:616. PubMed
  214. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  215. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  216. Dudek M, et al. 2021. Nature. 592:444. PubMed
  217. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  218. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  219. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  220. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  221. He Y, et al. 2022. Cells. 11:. PubMed
  222. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  223. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  224. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  225. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  226. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  227. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  228. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  229. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  230. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  231. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  232. Wang Z, et al. 2021. Nature. 595:426. PubMed
  233. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  234. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  235. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  236. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  237. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  238. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  239. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  240. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  241. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  242. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  243. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  244. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  245. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  246. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  247. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  248. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  249. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  250. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  251. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  252. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  253. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  254. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  255. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  256. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  257. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  258. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  259. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  260. Korin B, et al. 2020. Sleep. :43. PubMed
  261. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  262. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  263. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  264. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  265. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  266. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  267. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  268. Viant C, et al. 2020. Cell. 183:1298. PubMed
  269. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  270. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  271. Gaebler C, et al. 2020. bioRxiv. . PubMed
  272. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  273. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  274. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  275. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  276. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  277. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  278. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  279. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  280. Sibler E, et al. 2021. Cells. 10:. PubMed
  281. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  282. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  283. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  284. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  285. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  286. Spath S, et al. 2022. iScience. 25:104998. PubMed
  287. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  288. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  289. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  290. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  291. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  292. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  293. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  294. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  295. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  296. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  297. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  298. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  299. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  300. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  301. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  302. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  303. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  304. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  305. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  306. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  307. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 5    Revision Date: 05/20/2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account